Developer docs
API playgroundTry for free, no card

Search company profiles

858 Therapeutics

Full company profile

uuid0000cb5

Namestring
858 Therapeutics
Legal namestring
858 Therapeutics
Websiteurl
8five8tx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class small molecule therapeutics that exploit tumor dependencies in DNA damage response (DDR) pathways. The company is targeting oncology indications with high unmet medical need, principally BRCA-mutated advanced solid tumors including platinum-resistant, high-grade serous ovarian cancer and HR+/HER2- breast cancer. Its portfolio is organized around three interconnected biological focus areas: DDR (anchored by lead candidate ETX-19477), RNA epigenetics (built on the 2021 Gotham Therapeutics acquisition, including a METTL3 inhibitor program), and innate immunity (extending insights from predecessor Jecure Therapeutics' NLRP3 inflammasome work).

The company's lead program, ETX-19477, is an oral, potent, and selective small-molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), a DDR enzyme that removes PAR chains from proteins. PARG inhibition produces hyperPARylation and selective cancer cell death under replication stress in tumors with replication fork protection defects (including BRCA-mutated tumors) via a mechanism distinct from PARP inhibition, with potential to address PARP-inhibitor resistance. ETX-19477 is currently being evaluated in an open-label, multicenter Phase 1/2 study (ERADIC8; NCT06395519), with 45 patients enrolled in Phase 1a/b escalation/expansion and 53 patients in the expanded dataset for ASCO 2026; preliminary data showed a 57% objective response rate in the Phase 2-eligible subset. The internal discovery platform combines proprietary in vitro biochemical, biophysical, and cellular assays; early-stage discovery capabilities have been augmented through a 2024 collaboration with OpenBench, whose structure-based machine learning platform identifies chemical matter against 858-nominated targets.

858 Therapeutics is pre-revenue with no approved products or product sales; it funds operations through venture capital and partnership transactions. The company has raised an aggregate of approximately $110 million in disclosed venture funding across a $60 million Series A (September 2021, led by Versant Ventures) and a $50 million Series B (September 2024, led by Avidity Partners). Near-term revenue is not anticipated; any future revenue would derive from out-licensing deals, co-development partnerships (such as the OpenBench collaboration, under which OpenBench is eligible for success-based milestone payments), or eventual commercialization of approved drug candidates. The company is operationally headquartered in San Diego, CA (3115 Merryfield Row, Suite 110) with 11–50 employees and a stated plan to reach approximately 40 staff, and operates a multi-center U.S. clinical trial footprint for ETX-19477 development.

Short descriptiontext

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule DDR inhibitors for oncology, with lead asset ETX-19477 (an oral selective PARG inhibitor) in Phase 1/2 trials for BRCA-mutated ovarian and breast cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, small molecule drugs, PARG inhibitor development, DNA damage response, RNA modifying proteins
Industry2 codes
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1None (pre-revenue)
TypeLicensing Royalties
Description

858 Therapeutics is a clinical-stage biotechnology company with no approved products and no current product revenue. The company is funded by venture capital and uses proceeds to advance its pipeline of small molecule therapeutics through preclinical and clinical development; near-term revenue is not anticipated. Future revenue, if any, would be generated from out-licensing deals, partnerships, or commercialization of its oncology drug candidates.

8five8tx.com
Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Not applicable - pre-commercial clinical-stage biotech with no approved products and no publicly disclosed pricing.
ModelOther
Notes

No products are currently marketed; therefore no pricing has been disclosed.

8five8tx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class small molecule drugs targeting oncology and immunology. Its lead program, ETX-19477, is an oral, potent, and selective PARG inhibitor that exploits DNA damage response vulnerabilities in advanced solid tumors, including BRCA-mutated ovarian and breast cancers. The company also maintains a proprietary discovery platform spanning RNA-modifying protein biology and DNA damage response (DDR) drug discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 57% objective response rate (n=7) in Phase 2-eligible subset of BRCA-mutated platinum-resistant ovarian cancer and HR+/HER2- breast cancer patients treated with ETX-19477
+2 more records
Product overview1 text field

858 Therapeutics operates as a clinical-stage biotechnology company with a single integrated pipeline-and-platform model rather than a multi-product SaaS architecture. Its portfolio is organized around three interconnected focus areas in cancer biology: DNA damage repair (anchored by its lead candidate ETX-19477, an oral, potent, and selective PARG inhibitor in Phase 1/2 for advanced solid tumors), innate immunity (extending insights from predecessor company Jecure Therapeutics' NLRP3 inflammasome work), and RNA epigenetics (built on the Gotham Therapeutics acquisition and including the METTL3 inhibitor program). These pipeline programs are supported by an internal small-molecule discovery platform of proprietary in vitro biochemical, biophysical, and cellular assays, with external discovery capabilities augmented through a 2024 AI-enabled drug discovery collaboration with OpenBench. The company's product offering therefore consists of the lead clinical asset ETX-19477, the METTL3 inhibitor program, and the broader DNA Damage Response, RNA Epigenetics, and Innate Immunity pipeline programs it is advancing toward the clinic.

Product and service4 records
1ETX-19477
CategoryLead drug candidate (small molecule PARG inhibitor)
Description

ETX-19477 is an oral, potent, and selective small-molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), a key DNA damage response enzyme. It exploits cancer cell vulnerabilities related to replication stress and defects in replication fork protection pathways, with potential to address PARP-inhibitor resistance in solid tumors. ETX-19477 is being evaluated in an open-label, multicenter Phase 1/2 study (ERADIC8; NCT06395519) in patients with advanced solid tumors, including BRCA-mutated platinum-resistant ovarian cancer and HR+/HER2- breast cancer.

2METTL3 Inhibitor Program
CategoryDrug discovery program (RNA epitranscriptomics, acquired via Gotham Therapeutics)
Description

Program targeting METTL3, an RNA methyltransferase implicated in several cancers. Acquired through the September 2021 acquisition of Gotham Therapeutics and supports 858's RNA epigenetics portfolio alongside its PARG inhibitor and innate immunity programs.

3RNA Epigenetics & Innate Immunity Pipeline
CategoryDrug discovery pipeline / platform
Description

Portfolio of small molecule therapeutics directed against novel oncology and immunology targets beyond the lead PARG program, including proteins that regulate RNA modification (epitranscriptomics) and the innate immune response. Built on a proprietary discovery platform of in vitro biochemical, biophysical, and cellular assays to assess the impact of RNA-modifying proteins on disease biology.

4DNA Damage Response (DDR) Pipeline
CategoryDrug discovery pipeline (DDR precision oncology)
Description

Pipeline of first-in-class and best-in-class small molecule therapies designed to target tumor dependencies in DNA damage response (DDR) pathways. Lead program ETX-19477 exploits replication stress and replication fork protection defects to deliver precision oncology treatments for advanced solid tumors, including BRCA-mutated platinum-resistant ovarian cancer.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierStrategic / Co-DevelopmentTypeStrategic or Co-development PartnerAnnounced on2024-11-04
Description

Collaboration to discover small molecule inhibitors using OpenBench's structure-based machine learning platform, initially focused on an undisclosed target nominated by 858 Therapeutics. OpenBench identifies novel chemical series; 858 performs biochemical, biophysical, and cellular validation. OpenBench is eligible for success-based milestone payments for chemotypes meeting defined molecular properties; 858 retains full and exclusive rights to purchased chemotypes and is solely responsible for further R&D.

Strategic tierFoundational / Acquired EntityTypeStrategic or Co-development PartnerAnnounced on2021-09-20
Description

Acquired by 858 Therapeutics (terms undisclosed) at launch to support development of drugs targeting RNA-modifying proteins and METTL3 in cancer. Gotham is a New York City-based pioneer in epitranscriptomics and RNA modification enzymes, translating discoveries from the lab of Samie Jaffrey, M.D., Ph.D.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology biotech leveraging synthetic lethality and DNA damage response biology to develop precision small molecule therapeutics. Direct peer in mechanism-of-action and target patient population (BRCA/DDR-altered solid tumors).

2Artios Pharma
TypeDirect peer
Description

Clinical-stage oncology company developing small molecule inhibitors of DNA damage response (DDR) targets, including Polθ inhibitors and other DDR mechanisms. Closely comparable mechanism, stage, and indication overlap to 858's PARG program.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapies against novel targets in cancer, including DDR and kinase targets. Comparable as a clinical-stage, small-molecule, biomarker-defined oncology biotech.

TypeEmerging player
Description

Clinical-stage epigenetics oncology company acquired by MorphoSys; developed small molecules targeting chromatin/DNA-damage-related biology. Comparable in pipeline focus and stage (now part of a larger company).

TypeOthers
Description

Predecessor biotech acquired by Genentech in 2018, founded by the same team (Stafford, Veal, Bain) that founded 858 Therapeutics. Highly relevant as a founding-team comparable and as a model for 858's likely exit trajectory.

TypeBroad incumbent
Description

Developer of Rubraca (rucaparib), a PARP inhibitor approved for BRCA-mutated ovarian and prostate cancers. Direct same-mechanism comparator highlighting both the commercial benchmark for PARP/DDR drugs and the competitive threat to 858's PARG franchise.

TypeEmerging player
Description

Clinical-stage oncology biotech focused on DDR/small molecule therapeutics that was acquired by GSK. Comparable in mechanism focus (DDR-targeted small molecules) and outcome (acquired by large pharma at clinical stage).

TypeDirect peer
Description

Clinical-stage precision oncology company developing selective small molecule inhibitors including next-generation selective PARP inhibitors. Highly comparable in therapeutic area (PARP/DDR biology) and clinical-stage profile; 858's CMO Joseph Leveque previously served at Prelude-affiliated roles per management history.

TypeBroad incumbent
Description

Clinical-stage precision oncology company (acquired by BMS) whose KRAS inhibitor development was led by 858's current CMO Joseph Leveque. Comparable as a precision-oncology small molecule company at similar clinical stage that achieved a large-pharma exit.

TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic-lethal small molecules targeting DNA damage response vulnerabilities, with a similar biomarker-driven patient selection strategy in BRCA-mutated and DDR-deficient tumors. Direct competitor in the DDR precision oncology niche.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

858 Therapeutics

Precision Oncology Pharmaceuticals8five8tx.com

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule DDR inhibitors for oncology, with lead asset ETX-19477 (an oral selective PARG inhibitor) in Phase 1/2 trials for BRCA-mutated ovarian and breast cancers.

What 858 Therapeutics does

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class small molecule therapeutics that exploit tumor dependencies in DNA damage response (DDR) pathways. The company is targeting oncology indications with high unmet medical need, principally BRCA-mutated advanced solid tumors including platinum-resistant, high-grade serous ovarian cancer and HR+/HER2- breast cancer. Its portfolio is organized around three interconnected biological focus areas: DDR (anchored by lead candidate ETX-19477), RNA epigenetics (built on the 2021 Gotham Therapeutics acquisition, including a METTL3 inhibitor program), and innate immunity (extending insights from predecessor Jecure Therapeutics' NLRP3 inflammasome work).

The company's lead program, ETX-19477, is an oral, potent, and selective small-molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), a DDR enzyme that removes PAR chains from proteins. PARG inhibition produces hyperPARylation and selective cancer cell death under replication stress in tumors with replication fork protection defects (including BRCA-mutated tumors) via a mechanism distinct from PARP inhibition, with potential to address PARP-inhibitor resistance. ETX-19477 is currently being evaluated in an open-label, multicenter Phase 1/2 study (ERADIC8; NCT06395519), with 45 patients enrolled in Phase 1a/b escalation/expansion and 53 patients in the expanded dataset for ASCO 2026; preliminary data showed a 57% objective response rate in the Phase 2-eligible subset. The internal discovery platform combines proprietary in vitro biochemical, biophysical, and cellular assays; early-stage discovery capabilities have been augmented through a 2024 collaboration with OpenBench, whose structure-based machine learning platform identifies chemical matter against 858-nominated targets.

858 Therapeutics is pre-revenue with no approved products or product sales; it funds operations through venture capital and partnership transactions. The company has raised an aggregate of approximately $110 million in disclosed venture funding across a $60 million Series A (September 2021, led by Versant Ventures) and a $50 million Series B (September 2024, led by Avidity Partners). Near-term revenue is not anticipated; any future revenue would derive from out-licensing deals, co-development partnerships (such as the OpenBench collaboration, under which OpenBench is eligible for success-based milestone payments), or eventual commercialization of approved drug candidates. The company is operationally headquartered in San Diego, CA (3115 Merryfield Row, Suite 110) with 11–50 employees and a stated plan to reach approximately 40 staff, and operates a multi-center U.S. clinical trial footprint for ETX-19477 development.

858 Therapeutics firmographics

Firmographics
Name
858 Therapeutics
Legal name
858 Therapeutics
Website
https://8five8tx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
858 Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule DDR inhibitors for oncology, with lead asset ETX-19477 (an oral selective PARG inhibitor) in Phase 1/2 trials for BRCA-mutated ovarian and breast cancers.
Ownership category
akta.pro rank

858 Therapeutics industry classification

Industry
Product category
Precision Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Precision oncology therapeutics
  • Small molecule drugs
  • PARG inhibitor development
  • DNA damage response
  • RNA modifying proteins

Where 858 Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

858 Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. None (pre-revenue): 858 Therapeutics is a clinical-stage biotechnology company with no approved products and no current product revenue. The company is funded by venture capital and uses proceeds to advance its pipeline of small molecule therapeutics through preclinical and clinical development; near-term revenue is not anticipated. Future revenue, if any, would be generated from out-licensing deals, partnerships, or commercialization of its oncology drug candidates.

Pricing tiers

ModelBillingPrice
Other—Not applicable - pre-commercial clinical-stage biotech with no approved products and no publicly disclosed pricing.

Go-to-market motion2 records

Distribution channels2 records

858 Therapeutics product offering

Product offering

Core offering

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class small molecule drugs targeting oncology and immunology. Its lead program, ETX-19477, is an oral, potent, and selective PARG inhibitor that exploits DNA damage response vulnerabilities in advanced solid tumors, including BRCA-mutated ovarian and breast cancers. The company also maintains a proprietary discovery platform spanning RNA-modifying protein biology and DNA damage response (DDR) drug discovery.

Product overview

858 Therapeutics operates as a clinical-stage biotechnology company with a single integrated pipeline-and-platform model rather than a multi-product SaaS architecture. Its portfolio is organized around three interconnected focus areas in cancer biology: DNA damage repair (anchored by its lead candidate ETX-19477, an oral, potent, and selective PARG inhibitor in Phase 1/2 for advanced solid tumors), innate immunity (extending insights from predecessor company Jecure Therapeutics' NLRP3 inflammasome work), and RNA epigenetics (built on the Gotham Therapeutics acquisition and including the METTL3 inhibitor program). These pipeline programs are supported by an internal small-molecule discovery platform of proprietary in vitro biochemical, biophysical, and cellular assays, with external discovery capabilities augmented through a 2024 AI-enabled drug discovery collaboration with OpenBench. The company's product offering therefore consists of the lead clinical asset ETX-19477, the METTL3 inhibitor program, and the broader DNA Damage Response, RNA Epigenetics, and Innate Immunity pipeline programs it is advancing toward the clinic.

Differentiator

Problem solved

Functional benefit

Products and services

  • ETX-19477 ETX-19477 is an oral, potent, and selective small-molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), a key DNA damage response enzyme. It exploits cancer cell vulnerabilities related to replication stress and defects in replication fork protection pathways, with potential to address PARP-inhibitor resistance in solid tumors. ETX-19477 is being evaluated in an open-label, multicenter Phase 1/2 study (ERADIC8; NCT06395519) in patients with advanced solid tumors, including BRCA-mutated platinum-resistant ovarian cancer and HR+/HER2- breast cancer.
  • METTL3 Inhibitor Program Program targeting METTL3, an RNA methyltransferase implicated in several cancers. Acquired through the September 2021 acquisition of Gotham Therapeutics and supports 858's RNA epigenetics portfolio alongside its PARG inhibitor and innate immunity programs.
  • RNA Epigenetics & Innate Immunity Pipeline Portfolio of small molecule therapeutics directed against novel oncology and immunology targets beyond the lead PARG program, including proteins that regulate RNA modification (epitranscriptomics) and the innate immune response. Built on a proprietary discovery platform of in vitro biochemical, biophysical, and cellular assays to assess the impact of RNA-modifying proteins on disease biology.
  • DNA Damage Response (DDR) Pipeline Pipeline of first-in-class and best-in-class small molecule therapies designed to target tumor dependencies in DNA damage response (DDR) pathways. Lead program ETX-19477 exploits replication stress and replication fork protection defects to deliver precision oncology treatments for advanced solid tumors, including BRCA-mutated platinum-resistant ovarian cancer.

Quantifiable outcome

  • 57% objective response rate (n=7) in Phase 2-eligible subset of BRCA-mutated platinum-resistant ovarian cancer and HR+/HER2- breast cancer patients treated with ETX-19477
  • +2 more outcomes

Companies that use 858 Therapeutics

Customer profile

Named customers1 record

Ideal customer profiles2 records

858 Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

858 Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered strategic / co-development and foundational / acquired entity.

  • OpenBenchstrategic / co-developmentStrategic or Co-development Partner · 4 November 2024Collaboration to discover small molecule inhibitors using OpenBench's structure-based machine learning platform, initially focused on an undisclosed target nominated by 858 Therapeutics. OpenBench identifies novel chemical series; 858 performs biochemical, biophysical, and cellular validation. OpenBench is eligible for success-based milestone payments for chemotypes meeting defined molecular properties; 858 retains full and exclusive rights to purchased chemotypes and is solely responsible for further R&D.
  • Gotham Therapeuticsfoundational / acquired entityStrategic or Co-development Partner · 20 September 2021Acquired by 858 Therapeutics (terms undisclosed) at launch to support development of drugs targeting RNA-modifying proteins and METTL3 in cancer. Gotham is a New York City-based pioneer in epitranscriptomics and RNA modification enzymes, translating discoveries from the lab of Samie Jaffrey, M.D., Ph.D.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

858 Therapeutics competitors and assessment

Company assessment

Direct peers

  • Tango Therapeutics: Clinical-stage oncology biotech leveraging synthetic lethality and DNA damage response biology to develop precision small molecule therapeutics. Direct peer in mechanism-of-action and target patient population (BRCA/DDR-altered solid tumors).
  • Artios Pharma: Clinical-stage oncology company developing small molecule inhibitors of DNA damage response (DDR) targets, including Polθ inhibitors and other DDR mechanisms. Closely comparable mechanism, stage, and indication overlap to 858's PARG program.
  • Black Diamond Therapeutics: Clinical-stage precision oncology company developing small molecule therapies against novel targets in cancer, including DDR and kinase targets. Comparable as a clinical-stage, small-molecule, biomarker-defined oncology biotech.
  • Prelude Therapeutics: Clinical-stage precision oncology company developing selective small molecule inhibitors including next-generation selective PARP inhibitors. Highly comparable in therapeutic area (PARP/DDR biology) and clinical-stage profile; 858's CMO Joseph Leveque previously served at Prelude-affiliated roles per management history.
  • Repare Therapeutics: Clinical-stage precision oncology company developing synthetic-lethal small molecules targeting DNA damage response vulnerabilities, with a similar biomarker-driven patient selection strategy in BRCA-mutated and DDR-deficient tumors. Direct competitor in the DDR precision oncology niche.

Emerging players

  • Constellation Pharmaceuticals: Clinical-stage epigenetics oncology company acquired by MorphoSys; developed small molecules targeting chromatin/DNA-damage-related biology. Comparable in pipeline focus and stage (now part of a larger company).
  • Sierra Oncology: Clinical-stage oncology biotech focused on DDR/small molecule therapeutics that was acquired by GSK. Comparable in mechanism focus (DDR-targeted small molecules) and outcome (acquired by large pharma at clinical stage).

Others

  • Jecure Therapeutics: Predecessor biotech acquired by Genentech in 2018, founded by the same team (Stafford, Veal, Bain) that founded 858 Therapeutics. Highly relevant as a founding-team comparable and as a model for 858's likely exit trajectory.

Broad incumbents

  • Clovis Oncology: Developer of Rubraca (rucaparib), a PARP inhibitor approved for BRCA-mutated ovarian and prostate cancers. Direct same-mechanism comparator highlighting both the commercial benchmark for PARP/DDR drugs and the competitive threat to 858's PARG franchise.
  • Mirati Therapeutics: Clinical-stage precision oncology company (acquired by BMS) whose KRAS inhibitor development was led by 858's current CMO Joseph Leveque. Comparable as a precision-oncology small molecule company at similar clinical stage that achieved a large-pharma exit.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

858 Therapeutics social profiles

Digital presence

858 Therapeutics compliance and trust

Trust signal

Compliance1 record

858 Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

858 Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

858 Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

858 Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

858 Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 858 Therapeutics

What does 858 Therapeutics do?

858 Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class small molecule drugs targeting oncology and immunology. Its lead program, ETX-19477, is an oral, potent, and selective PARG inhibitor that exploits DNA damage response vulnerabilities in advanced solid tumors, including BRCA-mutated ovarian and breast cancers. The company also maintains a proprietary discovery platform spanning RNA-modifying protein biology and DNA damage response (DDR) drug discovery.

Is 858 Therapeutics a public or private company?

858 Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was 858 Therapeutics founded?

858 Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is 858 Therapeutics based?

858 Therapeutics is headquartered in San Diego, United States, in the North America region.

How does 858 Therapeutics make money?

One revenue line is on record: none (pre-revenue).

Who are 858 Therapeutics's main competitors?

Direct peers on record are Tango Therapeutics, Artios Pharma, Black Diamond Therapeutics, Prelude Therapeutics and Repare Therapeutics. Emerging players are Constellation Pharmaceuticals and Sierra Oncology. Jecure Therapeutics is listed as an others. Broad incumbents are Clovis Oncology and Mirati Therapeutics.

Does 858 Therapeutics have an API?

No public API is recorded for 858 Therapeutics.

What industry is 858 Therapeutics in?

858 Therapeutics's product category is Precision Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business Page858 Therapeutics Appoints Dr. Srini Ramanathan as Chief Executive Officer to Lead Next Phase of Company Growth858 Therapeutics appointed Srini Ramanathan as CEO and Jeffrey Stafford as Executive Chairman. Ramanathan will lead the company's clinical development of its lead candidate ETX-19477, a PARG inhibitor for solid tumors. Stafford will continue as Executive Chairman and become CEO of a Versant startup.San Diego Business Journal858 Developing Treatment for Breast, Ovarian Cancer Subtypes858 Therapeutics received FDA Fast Track designation for its lead drug ETX-19477 in BRCA-mutated breast and ovarian cancers. The company is enrolling patients in Phase 2A studies and plans further trials through 2027. It will need additional funding to complete clinical studies.Business Wire Blog858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer858 Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its PARG inhibitor, ETX-19477, to treat BRCA-mutated, HR+/HER2- unresectable or metastatic breast cancer. This designation enables access to expedited regulatory review processes, including potential eligibility for accelerated approval and priority review. The drug is currently being evaluated in an ongoing Phase 1/2 trial for advanced solid tumors.BioSpace858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting858 Therapeutics announced preliminary data from its Phase 1/2 trial of PARG inhibitor ETX-19477, to be presented at ASCO 2026. The data showed a 57% objective response rate in BRCA-mutated ovarian cancer and earlier-line breast cancer, with durable RECIST responses. The company plans to continue development, including combination approaches.Financial Post858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting858 Therapeutics announced preliminary safety and efficacy data from its first-in-human Phase 1/2 trial of PARG inhibitor ETX-19477, to be presented at the 2026 ASCO Annual Meeting, with a 57% objective response rate observed in a subset of seven BRCA-mutated ovarian cancer and HR+/HER2- breast cancer patients meeting Phase 2 eligibility criteria. The drug demonstrated a favorable safety profile with low rates of hematologic toxicity and durable RECIST responses in both tumor types, representing the first clinical proof-of-concept for PARG inhibition in these cancers. The company is currently enrolling patients in Phase 2 monotherapy expansion cohorts and plans to pursue combination approaches to expand treatable patient populations.The Canadian Press NewsLenovo Group: Q4 and Full Year Financial Results 2025/26Lenovo reported Q4 and full-year fiscal 2025/26 results, with Q4 revenue of US$21.6 billion up 27% year-on-year and adjusted net income of US$559 million, double the prior year. Full-year revenue reached US$83.1 billion, up 20%, and adjusted net income grew 42% to US$2 billion. AI-related revenue grew 84% in Q4 to 38% of total revenue.The Canadian Press NewsGlobal Real Assets Trust Announces Filing of Final Prospectus for Offering of Preferred UnitsGlobal Real Assets Trust filed a final prospectus for an offering of 6.85% cumulative redeemable preferred units at $25 each. The offering is expected to close on May 29, 2026, with net proceeds used for a special redemption right and investment in real assets and infrastructure.The Canadian Press News858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting858 Therapeutics announced preliminary data from its Phase 1/2 trial of PARG inhibitor ETX-19477, to be presented at ASCO 2026. The data from 45 patients showed a 57% objective response rate in 7 patients, with durable responses in BRCA-mutated ovarian and breast cancer. The company is enrolling patients in Phase 2 expansion cohorts.Business Wire Blog858 Therapeutics and OpenBench Launch Small Molecule Drug Discovery Collaboration858 Therapeutics and OpenBench announced a collaboration to discover small molecule inhibitors using OpenBench's structure-based machine learning platform, focusing initially on an undisclosed target. OpenBench will identify novel chemical series, while 858 will validate them, with OpenBench eligible for success-based milestone payments. Detailed financial terms were not disclosed.Pulse 2.0858 Therapeutics: Drug Discovery Company Raises $50 Million (Series B)858 Therapeutics raised $50 million in a Series B led by Avidity Partners, with participation from Insight Partners, Mirae Asset Capital, and Alexandria Venture Investments. The company will use the funds to advance its PARG inhibitor ETX-19477, which is in a Phase 1 trial for advanced solid tumors. Monal Mehta will join the board.